This depletion can manifest itself in ways that might include impaired nutrient absorption and assimilation, gut, lung, eye, blood, skin, and brain issues, keloid scarring, mitochondrial stress for lower energy output, DNA mutation, mass oxidation, and free radical overload
Clinical trials show that approximately 8 to 12 percent of patients discontinue GLP-1 therapy specifically due to side effectsthe vast majority experience acceptable symptoms within the first month
Does insurance cover GLP-1 weight loss medications
This is ultimately a clinical decision for you and your doctor, but trial and real-world data suggest practical patterns: Wegovy may suit better if cardiovascular disease is a key concern as semaglutide has a proven and licensed cardiovascular risk-reduction indication